← Leaderboards
Yanhong Shi
Beckman Research Institute/City Of Hope
$18,199,865
Attributed
$19,321,840
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,321,840 · 11
By mechanism
R01$6,666,084 · 4
U01$5,276,950 · 1
RF1$5,077,897 · 2
RC1$1,000,000 · 1
R21$672,262 · 2
R56$628,647 · 1
Top collaborators
- Yadong Huang5 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseCellsMouse ModelNeuronsElementsPlayGenesBrainSignal PathwayInduced Pluripotent Stem CellHuman DiseaseNeurodegenerative DisordersNerve Stem CellEffective TherapySourceGenerationsTechnologyFibroblastsEpigenetic ProcessPhenotypeSomatic CellDisease ModelAge Related
Grant awards (26)
Define the effect of CLU SNP on the risk to Alzheimer's disease$634,699
R01 · FY2025 · AG · contact PI
Develop age-relevant glial cellular models using human directly reprogrammed cells$431,200
R01 · FY2025 · AG · contact PI
Develop age-relevant glial cellular models using human directly reprogrammed cells$440,000
R01 · FY2024 · AG · contact PI
A Human iPSC-based Cell Therapy for Canavan Disease$1,759,864
U01 · FY2023 · NS · contact PI
Develop age-relevant glial cellular models using human directly reprogrammed cells$440,000
R01 · FY2023 · AG · contact PI
Define the effect of CLU SNP on the risk to Alzheimer's disease$1,942,962
RF1 · FY2022 · AG · contact PI
A Human iPSC-based Cell Therapy for Canavan Disease$1,759,534
U01 · FY2022 · NS · contact PI
Develop age-relevant glial cellular models using human directly reprogrammed cells$440,000
R01 · FY2022 · AG · contact PI
A Human iPSC-based Cell Therapy for Canavan Disease$1,757,552
U01 · FY2021 · NS · contact PI
Modeling Alzheimerâs disease using directly reprogrammed isogenic neural cells$445,140
R01 · FY2021 · AG · contact PI
Develop age-relevant glial cellular models using human directly reprogrammed cells$440,000
R01 · FY2021 · AG · contact PI
Modeling Alzheimerâs disease using directly reprogrammed isogenic neural cells$445,140
R01 · FY2020 · AG · contact PI
Uncovering the molecular and cellular mechanisms underlying AD using CRISPR/Cas9-edited isogenic neural cells$628,647
R56 · FY2019 · AG · contact PI
Modeling Alzheimerâs disease using directly reprogrammed isogenic neural cells$445,140
R01 · FY2019 · AG · contact PI
ApoE2 in Alzheimer's disease: the neuroprotective effects and mechanisms$3,134,935
RF1 · FY2018 · AG · contact PI
Modeling Alzheimerâs disease using directly reprogrammed isogenic neural cells$445,140
R01 · FY2018 · AG · contact PI
Identify ZIKV host factors with an improved CRISPR-based genome-wide knockout screen$259,500
R21 · FY2018 · AI · contact PI
Modeling Alzheimerâs disease using directly reprogrammed isogenic neural cells$463,390
R01 · FY2017 · AG · contact PI
Derivation of human pluripotent stem cells using small molecules$1,000,000
RC1 · FY2010 · NS · contact PI
Orphan nuclear receptor TLX signaling in neural stem cells$365,991
R01 · FY2010 · NS · contact PI
Orphan nuclear receptor TLX signaling in neural stem cells$369,688
R01 · FY2009 · NS · contact PI
Orphan nuclear receptor TLX signaling in neural stem cells$369,688
R01 · FY2008 · NS · contact PI
Orphan nuclear receptor TLX signaling in neural stem cells$121,180
R01 · FY2008 · NS · contact PI
Orphan nuclear receptor TLX signaling in neural stem cells$369,688
R01 · FY2007 · NS · contact PI
TLX Ligands in Neural Stem Cells & Neurodegeneration$184,612
R21 · FY2007 · NS · contact PI
TLX Ligands in Neural Stem Cells & Neurodegeneration$228,150
R21 · FY2006 · NS · contact PI